While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Puma Biotechnology PBYI reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an ...

Puma Biotechnology is a commercial-stage biotech with a struggling approved drug, neratinib, but potential for gains. The company is focused on refining current indications for neratinib and ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the best affordable biotech stocks to invest in now. Puma Biotechnology, Inc. (NASDAQ:PBYI) reported its fiscal Q2 2025 results on August 7, with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now. In a report released on August 8, Gena Wang from Barclays maintained a Sell rating on Puma ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...